BioCardia, Inc. Selling, General and Administrative Expense
BioCardia, Inc. (BCDA) reported Selling, General and Administrative Expense of $730.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-12
- BioCardia, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $730.00K, a 6.88% increase year-over-year.
- BioCardia, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $1.03M, a 13.80% decline year-over-year.
- BioCardia, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $885.00K, a 2.32% decline year-over-year.
- BioCardia, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $552.00K, a 33.09% decline year-over-year.
- BioCardia, Inc. selling, general and administrative expense for fiscal 2025 was $3.32M, a 9.69% decline from fiscal 2024.
- BioCardia, Inc. selling, general and administrative expense for fiscal 2024 was $3.67M, a 16.45% decline from fiscal 2023.
- BioCardia, Inc. selling, general and administrative expense for fiscal 2023 was $4.39M, a 0.54% decline from fiscal 2022.
- BioCardia, Inc. selling, general and administrative expense for fiscal 2022 was $4.42M, a 13.13% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $730.00K 10-Q · filed 2026-08-12 | $1.76M 10-Q · filed 2026-08-12 | $2.65M derived: sum of 3 quarters · filed 2026-08-12 | $3.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.03M 10-Q · filed 2026-05-15 | $1.92M derived: sum of 2 quarters · filed 2026-05-15 | $2.47M derived: sum of 3 quarters · filed 2026-05-15 | $3.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $885.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $1.44M derived: sum of 2 quarters · filed 2026-03-24 | $2.12M derived: sum of 3 quarters · filed 2026-08-12 | $3.32M 10-K · filed 2026-03-24 |
| 2025-09-30 | $552.00K 10-Q · filed 2025-11-12 | $1.24M derived: sum of 2 quarters · filed 2026-08-12 | $2.43M 10-Q · filed 2025-11-12 | $3.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $683.00K 10-Q · filed 2026-08-12 | $1.88M 10-Q · filed 2026-08-12 | $2.79M derived: sum of 3 quarters · filed 2026-08-12 | $3.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.20M 10-Q · filed 2026-05-15 | $2.10M derived: sum of 2 quarters · filed 2026-05-15 | $2.93M derived: sum of 3 quarters · filed 2026-05-15 | $3.78M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $906.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $1.73M derived: sum of 2 quarters · filed 2026-03-24 | $2.58M derived: sum of 3 quarters · filed 2026-03-24 | $3.67M 10-K · filed 2026-03-24 |
| 2024-09-30 | $825.00K 10-Q · filed 2025-11-12 | $1.68M derived: sum of 2 quarters · filed 2025-11-12 | $2.77M 10-Q · filed 2025-11-12 | $3.71M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $852.00K 10-Q/A · filed 2025-10-29 | $1.94M 10-Q/A · filed 2025-10-29 | $2.88M derived: sum of 3 quarters · filed 2025-10-29 | $3.96M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-03-31 | $1.09M 10-Q · filed 2025-05-14 | $2.03M derived: sum of 2 quarters · filed 2025-05-14 | $3.11M derived: sum of 3 quarters · filed 2025-05-14 | $4.29M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $941.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $2.02M derived: sum of 2 quarters · filed 2025-03-26 | $3.21M derived: sum of 3 quarters · filed 2025-03-26 | $4.39M 10-K · filed 2025-03-26 |
| 2023-09-30 | $1.08M 10-Q · filed 2024-11-13 | $2.26M derived: sum of 2 quarters · filed 2024-11-13 | $3.45M 10-Q · filed 2024-11-13 | $4.38M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.18M 10-Q · filed 2024-08-13 | $2.37M 10-Q · filed 2024-08-13 | $3.29M derived: sum of 3 quarters · filed 2024-08-13 | $4.42M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.19M 10-Q · filed 2024-05-14 | $2.11M derived: sum of 2 quarters · filed 2024-05-14 | $3.24M derived: sum of 3 quarters · filed 2024-05-14 | $4.41M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $924.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $2.05M derived: sum of 2 quarters · filed 2024-03-27 | $3.22M derived: sum of 3 quarters · filed 2024-03-27 | $4.42M 10-K · filed 2024-03-27 |
| 2022-09-30 | $1.13M 10-Q · filed 2023-11-08 | $2.29M derived: sum of 2 quarters · filed 2023-11-08 | $3.50M 10-Q · filed 2023-11-08 | $4.92M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $1.17M 10-Q · filed 2023-08-09 | $2.37M 10-Q · filed 2023-08-09 | $3.79M derived: sum of 3 quarters · filed 2023-08-09 | $5.08M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.20M 10-Q · filed 2023-05-10 | $2.63M derived: sum of 2 quarters · filed 2023-05-10 | $3.92M derived: sum of 3 quarters · filed 2023-05-10 | $5.11M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $2.71M derived: sum of 2 quarters · filed 2023-03-29 | $3.91M derived: sum of 3 quarters · filed 2023-03-29 | $5.09M 10-K · filed 2023-03-29 |
| 2021-09-30 | $1.29M 10-Q · filed 2022-11-09 | $2.48M derived: sum of 2 quarters · filed 2022-11-09 | $3.66M 10-Q · filed 2022-11-09 | $4.88M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.20M 10-Q · filed 2022-08-10 | $2.37M 10-Q · filed 2022-08-10 | $3.59M derived: sum of 3 quarters · filed 2022-08-10 | $5.00M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $1.18M 10-Q · filed 2022-05-11 | $2.40M derived: sum of 2 quarters · filed 2022-05-11 | $3.80M derived: sum of 3 quarters · filed 2022-05-11 | $5.18M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $2.63M derived: sum of 2 quarters · filed 2022-03-29 | $4.00M derived: sum of 3 quarters · filed 2022-03-29 | $5.86M 10-K · filed 2022-03-29 |
| 2020-09-30 | $1.41M 10-Q · filed 2021-11-10 | $2.79M derived: sum of 2 quarters · filed 2021-11-10 | $4.64M 10-Q · filed 2021-11-10 | $6.18M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $1.38M 10-Q · filed 2021-08-12 | $3.23M 10-Q · filed 2021-08-12 | $4.78M derived: sum of 3 quarters · filed 2021-08-12 | $6.17M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.86M 10-Q · filed 2021-05-13 | $3.40M derived: sum of 2 quarters · filed 2021-05-13 | $4.79M derived: sum of 3 quarters · filed 2021-05-13 | $6.23M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $2.93M derived: sum of 2 quarters · filed 2021-03-30 | $4.37M derived: sum of 3 quarters · filed 2021-03-30 | $6.00M 10-K · filed 2021-03-30 |
| 2019-09-30 | $1.39M 10-Q · filed 2020-11-10 | $2.83M derived: sum of 2 quarters · filed 2020-11-10 | $4.46M 10-Q · filed 2020-11-10 | $5.90M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $1.44M 10-Q · filed 2020-08-13 | $3.07M 10-Q · filed 2020-08-13 | $4.51M derived: sum of 3 quarters · filed 2020-08-13 | $5.79M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $1.63M 10-Q · filed 2020-05-15 | $3.07M derived: sum of 2 quarters · filed 2020-05-15 | $4.36M derived: sum of 3 quarters · filed 2020-05-15 | $5.68M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-09 | $2.73M derived: sum of 2 quarters · filed 2020-04-09 | $4.05M derived: sum of 3 quarters · filed 2020-04-09 | $5.76M 10-K · filed 2020-04-09 |
| 2018-09-30 | $1.28M 10-Q · filed 2019-11-19 | $2.61M derived: sum of 2 quarters · filed 2019-11-19 | $4.32M 10-Q · filed 2019-11-19 | $6.00M derived: sum of 4 quarters · filed 2020-04-09 |
| 2018-06-30 | $1.32M 10-Q · filed 2019-08-14 | $3.03M 10-Q · filed 2019-08-14 | $4.72M derived: sum of 3 quarters · filed 2020-04-09 | $6.04M derived: sum of 4 quarters · filed 2020-04-09 |
| 2018-03-31 | $1.71M 10-Q · filed 2019-05-15 | $3.39M derived: sum of 2 quarters · filed 2020-04-09 | $4.72M derived: sum of 3 quarters · filed 2020-04-09 | $6.30M derived: sum of 4 quarters · filed 2020-04-09 |
| 2017-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-09 | $3.01M derived: sum of 2 quarters · filed 2020-04-09 | $4.59M derived: sum of 3 quarters · filed 2020-04-09 | $6.39M 10-K · filed 2020-04-09 |
| 2017-09-30 | $1.32M 10-Q · filed 2018-11-08 | $2.90M derived: sum of 2 quarters · filed 2018-11-08 | $4.71M 10-Q · filed 2018-11-08 | $6.44M derived: sum of 4 quarters · filed 2019-04-02 |
| 2017-06-30 | $1.58M 10-Q · filed 2018-08-09 | $3.39M 10-Q · filed 2018-08-09 | $5.12M derived: sum of 3 quarters · filed 2019-04-02 | $6.04M derived: sum of 4 quarters · filed 2019-04-02 |
| 2017-03-31 | $1.80M 10-Q · filed 2018-05-10 | $3.54M derived: sum of 2 quarters · filed 2019-04-02 | $4.46M derived: sum of 3 quarters · filed 2019-04-02 | $5.33M derived: sum of 4 quarters · filed 2019-04-02 |
| 2016-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-02 | $2.65M derived: sum of 2 quarters · filed 2019-04-02 | $3.52M derived: sum of 3 quarters · filed 2019-04-02 | $4.11M 10-K · filed 2019-04-02 |
| 2016-09-30 | $919.00K 10-Q · filed 2017-11-09 | $1.79M derived: sum of 2 quarters · filed 2017-11-09 | $2.38M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $869.00K 10-Q · filed 2017-08-14 | $1.46M 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $587.00K 10-Q · filed 2017-05-11 | |||
| 2015-12-31 | $3.73M 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |